Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0012044747
Thu, 25.04.2024
Redcare Pharmacy N.V.
Redcare’s fast double-digit growth continues in Q1, and at a 2.1% positive margin. Also in Q1, after many years, breakthrough in online e-Rx in Germany.
Group sales of EUR 560M in Q1, up 51% from prior year.
Non-Rx sales growth 20% to EUR 404M; Rx sales up 7% in Germany, following additional marketing and communication campaigns.
Adj. EBITDA ma [ … ]
Tue, 23.04.2024
Redcare Pharmacy N.V.
Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.
Fully digital redemption method to be integrated in Redcare’s Shop Apotheke mobile app in Germany.
Expected to be available for customers by early May.
Redcare ideally positioned to serve e-Rx customers in the multi-billion-euro German prescription market.
Sevenum, the Neth [ … ]
Thu, 18.04.2024
Redcare Pharmacy N.V.
Redcare Pharmacy's Annual General Meeting 2024 approved all agenda items. Dirk Brüse and Lode Fastré new members of the Managing Board.
Sevenum, the Netherlands, 18 April, 2024. At Redcare Pharmacy’s Annual General Meeting held yesterday, shareholders voted with an absolute majority for all agenda items, among others the appointment of Dirk Brüse [ … ]
Tue, 05.03.2024
Redcare Pharmacy N.V.
Successful completion of a record year for Redcare Pharmacy: growth 49%, adj. EBITDA margin up 3.7pp to 3%; guidance achieved in all its elements.
Total Group sales EUR 1.8 bn, up 49% vs. prior year.
Non-Rx sales EUR 1.3 bn, up 25% vs. prior year.
Adj. EBITDA margin 3% for full year 2023, +3.7pp vs. 2022, with major improvements in both DACH an [ … ]
Mon, 04.03.2024
Redcare Pharmacy N.V.
Seamless transition for continuity and stability: Redcare Pharmacy with internal succession plan for Stephan Weber (CCO) and Marc Fischer (CIO).
Dirk Brüse and Lode Fastré, both long-standing managers at Redcare Pharmacy, are to succeed Stephan Weber and Marc Fischer as CCO and CIO.
Board members and founders see the ideal time for the leadership [ … ]
Wed, 10.01.2024
Redcare Pharmacy N.V.
Another successful fast-growth quarter for Redcare Pharmacy, completing full year 2023 at the very upper end of its guidance.
Q4 total sales EUR 531M, year-over-year growth 62%, excluding MediService 23%.
Full year total sales EUR 1.8bn vs. guidance of EUR 1.7-1.8bn, a growth of 49%. Excluding MediService, growth was 24%.
Non-Rx sales grew 23% [ … ]
Tue, 31.10.2023
Redcare Pharmacy N.V.
Redcare Pharmacy: continued very fast growth combined with major margin lift; adj. EBITDA 3.2% in Q3, vs. 0.4% last year.
Group sales up 67% to EUR 476M in Q3 (9M up 45% to EUR 1.3bn).
Non-Rx sales growth 27% in Q3 to EUR 319M (9M up 26% to EUR 979M).
MediService performing on plan; full-year outlook confirmed.
Adj. EBITDA margin 3.2% in Q3 (9M [ … ]
Thu, 05.10.2023
Redcare Pharmacy N.V.
Redcare Pharmacy continues to successfully grow fast in all its markets.
Total sales growth 67% in Q3, to EUR 475M.
Year-to-date total sales growth 45%, to EUR 1.3bn.
Organic growth (i.e. excluding sales of MediService) 26% to EUR 358M in Q3 and 24% to EUR 1.1bn year to date.
Non-Rx growth 27% in Q3 (to EUR 319M) and year to date 26% (to EUR 97 [ … ]
Tue, 01.08.2023
Redcare Pharmacy N.V.
Redcare Pharmacy Q2 2023: While fast sales growth continues unabated at 46%, adj. EBITDA margin improved 5.3pp year over year to 3.2%. Company raises full-year guidance.
Total sales up 46% in Q2 to EUR 420M and by 34% in H1 to EUR 792M.
Excluding MediService AG (consolidated since mid-May), sales up 25% in Q2 and 24% in H1.
Non-Rx growth 27% in [ … ]
Tue, 01.08.2023
Redcare Pharmacy N.V.
Redcare Pharmacy Q2 2023: While fast sales growth continues unabated at 46%, adj. EBITDA margin improved 5.3pp year over year to 3.2%. Company raises full-year guidance.
Total sales up 46% in Q2 to EUR 420M and by 34% in H1 to EUR 792M.
Excluding MediService AG (consolidated since mid-May), sales up 25% in Q2 and 24% in H1.
Non-Rx growth 27% in [ … ]